ReviewRambam Maimonides medical journal2017
Comorbidities in Patients with Psoriatic Arthritis.
Review in Rambam Maimonides medical journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Cost and Cost Effectiveness of Treatments for Psoriatic Arthritis: A Systematic Literature Review.PharmacoEconomics · 2018Pooled it
- Trial
- Observational
- Prevalence and factors associated with fatigue in patients with psoriatic arthritis: a systematic review and meta-analysis.BMC rheumatology · 2025Article
- Depression and Anxiety in Patients with Psoriasis: A Comprehensive Analysis Combining Bibliometrics, Latent Dirichlet Allocation, and HJ-Biplot.Healthcare (Basel, Switzerland) · 2025Review
- Central obesity in psoriatic arthritis: associations with disease activity, function, and quality of life in a real-world cohort.Frontiers in medicine · 2025Article
- The Paradox of Osteoporosis in Spondyloarthropathies.Mediterranean journal of rheumatology · 2024Review
- Apremilast for biologic-naïve, peripheral psoriatic arthritis, including patients with early disease: results from the APROACH observational prospective study.Rheumatology international · 2023Observational
- Review
- Psoriatic arthritis: review of potential biomarkers predicting response to TNF inhibitors.Inflammopharmacology · 2023Review
- Treatment patterns and health care costs among patients with psoriatic arthritis treated with biologic or targeted synthetic disease-modifying antirheumatic drugs.Journal of managed care & specialty pharmacy · 2022Article
- Psoriatic arthritis: prospects for the future.Therapeutic advances in musculoskeletal disease · 2022Review
- Real-World Treatment Patterns and Healthcare Costs in Patients with Psoriatic Arthritis Treated with Ixekizumab: A Retrospective Study.ACR open rheumatology · 2021Article
- Update on the therapeutic management of patients with either psoriatic arthritis or ulcerative colitis: focus on the JAK inhibitor tofacitinib.Therapeutic advances in musculoskeletal disease · 2021Review
- Psoriatic arthritis epidemiology, comorbid disease profiles and risk factors: results from a claims database analysis.Rheumatology advances in practice · 2020Article
- Impact of Clinical Specialty Setting and Geographic Regions on Disease Management in Patients with Psoriatic Arthritis in the United States: A Multicenter Observational Study.American journal of clinical dermatology · 2019Observational
- Treatment Patterns Among Patients with Psoriatic Arthritis Treated with a Biologic in the United States: Descriptive Analyses from an Administrative Claims Database.Journal of managed care & specialty pharmacy · 2018Observational
- Role of the IL-23/IL-17 Axis in Psoriasis and Psoriatic Arthritis: The Clinical Importance of Its Divergence in Skin and Joints.International journal of molecular sciences · 2018Review
- Facing the Unseen - Metabolic Syndrome in Psoriatic Arthritis.Current health sciences journalArticle
- Overlap of Psoriatic Arthritis and Dermatomyositis.Journal of investigative medicine high impact case reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epidemiological studies have shown that patients with psoriatic arthritis (PsA) are often affected by numerous comorbidities that carry significant morbidity and mortality. Reported comorbidities include diabetes mellitus, obesity, metabolic syndrome, cardiovascular diseases, osteoporosis, inflammatory bowel disease, autoimmune eye disease, non-alcoholic fatty liver disease, depression, and fibromyalgia. All health care providers for patients with PsA should recognize and monitor those comorbidities, as well as understand their effect on patient management to ensure an optimal clinical outcome.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.